PXB-cells Sales
First written in FY2016. 9 of 27 entries say "Advanced", first in FY2018. Latest entry: 2026-08-14.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Product sales 1,209,942 111.9」
Product sales revenue was ¥1,209,942 thousand, or 111.9% of the year-earlier level, demonstrating performance consistent with the policy of shifting the focus from contracted testing services to product sales. - FY2026-H1Sluggish overseas PXB-cells salesAnnual report
「Revenue was also slightly below the year-earlier level because overseas PXB-cells sales lost momentum.」
The company states that, despite its policy of expanding sales of PXB mouse-related products, overseas PXB-cells sales lost momentum during the interim consolidated accounting period, leaving revenue slightly below the year-earlier level. - FY2025AdvancedAnnual report
「Product sales 1,081,470 81.9」
Product sales revenue was ¥1,081,470 thousand, or 81.9% of the year-earlier level, demonstrating performance consistent with the policy of prioritizing product sales. - FY2024-Q3AdvancedAnnual report
「In the safety-related field, awareness of PXB mice as a useful tool in drug development for nucleic acid pharmaceuticals and gene therapy has increased, and performance was substantially above the previous year due to the acquisition of large mouse-sales orders.」
For PXB mouse product sales, states that awareness increased in the nucleic acid pharmaceuticals and gene therapy fields and that large orders were acquired. - FY2024-Q2AdvancedAnnual report
「In the safety-related field, mouse sales and other products remained solid, and stable demand for PXB mice in nucleic acid pharmaceuticals resulted in performance substantially above the previous year.」
In connection with the shift from contract-testing services to product sales, states that mouse sales and other products in the safety-related field remained solid and order intake was substantially above the previous year. - FY2024-Q1AdvancedAnnual report
「Orders for mouse sales and other products in the safety-related field were broadly in line with plan, resulting in performance above the previous year.」
States that orders for PXB mouse sales and other products in the safety-related field were broadly in line with plan and exceeded the previous year. - FY2023RestatedAnnual report
「At the same time, to promote the adoption of our products, we plan to further strengthen collaboration with contract research organizations for nonclinical testing in Japan and overseas, in addition to contract-testing services at our own facilities, and expand domestic and overseas sales of products including PXB mice and PXB-cells.」
Reconfirms the policy of expanding collaboration with contract research organizations for nonclinical testing in Japan and overseas and sales of PXB mice and PXB-cells, in addition to contract-testing services. - FY2023-Q3AdvancedAnnual report
「Revenue substantially exceeded the same period of the previous year because contract testing for anti-hepatitis B drugs and mouse sales in overseas markets increased significantly.」
States that mouse sales, in addition to contract-testing services, achieved substantial growth in overseas markets. - FY2023-Q2RestatedAnnual report
「At the same time, by shifting from our existing contract-testing services toward PXB mouse sales, we will concentrate management resources on mouse production and seek to stabilize our earnings base.」
Reconfirms the policy of shifting from contract-testing services to PXB mouse sales and stabilizing the earnings base by concentrating management resources on mouse production. - FY2023-Q1RestatedAnnual report
「At the same time, by shifting from our existing contract-testing services toward PXB mouse sales, we will concentrate management resources on mouse production and seek to stabilize our earnings base.」
Reconfirms the policy of stabilizing the earnings base by shifting from contract-testing services to PXB mouse sales and concentrating management resources on mouse production. - FY2022-Q1RestatedAnnual report
「At the same time, by shifting from our existing contract-testing services toward PXB mouse sales, we will concentrate management resources on mouse production and seek to stabilize our earnings base.」
Reconfirms the policy of shifting from contract-testing services to PXB mouse sales and concentrating management resources on mouse production. - FY2021-Q2RestatedAnnual report
「At the same time, by shifting from our existing contract-testing services toward PXB mouse sales, we will concentrate management resources on mouse production and seek to stabilize our earnings base.」
Reconfirms the policy of stabilizing the earnings base by shifting from contract-testing services to PXB mouse sales and concentrating management resources on mouse production. - FY2021-Q1RaisedAnnual report
「At the same time, by shifting from our existing contract-testing services toward PXB mouse sales, we will concentrate management resources on mouse production and seek to stabilize our earnings base.」
Further specifies the previous policy of expanding product sales as a shift from contract-testing services to PXB mouse sales and a concentration of management resources on mouse production. - FY2020RestatedAnnual report
「In addition to contract-testing services at our own facilities, we plan to further strengthen collaboration with contract research organizations for nonclinical testing in Japan and overseas and expand domestic and overseas sales of products including PXB mice and PXB-cells.」
Reconfirms the plan to expand domestic and overseas sales of PXB mice and PXB-cells, in addition to contract-testing services. - FY2019RaisedAnnual report
「To promote the adoption of our products, we plan to expand sales in Japan and overseas of products including PXB mice and PXB-cells, in addition to our existing contract-testing services.」
Explicitly states the plan to expand domestic and overseas sales of products including PXB mice and PXB-cells, in addition to the existing contract-testing services. - FY2019-Q3Loss of expected annual PXB-cells contractAnnual report
「Although an expected annual contract for PXB-cells was lost,」
States that the expected annual PXB-cells contract was lost. - FY2019-Q2PXB-cells sales declined and fell short of planAnnual report
「In DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) and other areas, which the Group positions as growth areas because they can target many new drugs, both orders and revenue exceeded the prior-year period, but fell short of the initial plan due to testing delays and lower sales of PXB-cells.」
States that PXB-cells sales declined and, together with delays in testing, caused revenue from DMPK/Tox testing and other services to fall below the initial plan. - FY2019-Q1Some PXB-cells sales projects fell short of expected order valueAnnual report
「In DMPK/Tox testing (drug metabolism and pharmacokinetics testing and safety testing) and other services, which the group positions as a growth area because they cover many new drugs, some PXB-cells sales projects generated less order value than expected, although revenue was broadly in line with plan.」
States that some PXB-cells sales projects generated less order value than expected. Meanwhile, revenue from DMPK/Tox testing and other services was broadly in line with plan. - FY2018AdvancedAnnual report
「DMPK/Tox testing (drug metabolism and pharmacokinetics testing and safety testing), which the group positions as a growth area because it covers many new drugs, benefited from useful academic presentations that led to increased orders in the new chemicals application area and growth in PXB-cells sales, while PXB mouse sales in overseas markets remained sluggish.」
States that PXB-cells sales grew as part of the full-year business progress. - FY2017RestatedAnnual report
「The PXB-cells we provide consist of hepatocytes collected by perfusion from PXB mice as needed and can be supplied fresh without freezing.」
Reconfirms the business of supplying PXB-cells as fresh human hepatocytes. - FY2016First statedAnnual report
「The PXB-cells we provide consist of hepatocytes collected by perfusion from PXB mice as needed and can be supplied fresh without freezing.」
Describes the business of supplying fresh human hepatocytes obtained from PXB mice as PXB-cells.